NTBL Stock Overview
A clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Notable Labs, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.02 |
| 52 Week High | US$5.27 |
| 52 Week Low | US$0.83 |
| Beta | 0 |
| 1 Month Change | 4.62% |
| 3 Month Change | -12.07% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| NTBL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.4% | 3.2% | 1.7% |
| 1Y | n/a | 6.2% | 26.3% |
Return vs Industry: Insufficient data to determine how NTBL performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how NTBL performed against the US Market.
Price Volatility
| NTBL volatility | |
|---|---|
| NTBL Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NTBL's share price has been volatile over the past 3 months.
Volatility Over Time: NTBL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 16 | Thomas Bock | www.notablelabs.com |
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population.
Notable Labs, Ltd. Fundamentals Summary
| NTBL fundamental statistics | |
|---|---|
| Market cap | US$9.20m |
| Earnings (TTM) | -US$8.76m |
| Revenue (TTM) | US$311.00k |
29.6x
P/S Ratio-1.1x
P/E RatioIs NTBL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTBL income statement (TTM) | |
|---|---|
| Revenue | US$311.00k |
| Cost of Revenue | US$197.00k |
| Gross Profit | US$114.00k |
| Other Expenses | US$8.87m |
| Earnings | -US$8.76m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 36.66% |
| Net Profit Margin | -2,816.08% |
| Debt/Equity Ratio | 1.3% |
How did NTBL perform over the long term?
See historical performance and comparison